Literature DB >> 12644703

Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.

Alonso Heredia1, Charles Davis, Anthony Amoroso, Joyelle K Dominique, Nhut Le, Erin Klingebiel, Elise Reardon, Davide Zella, Robert R Redfield.   

Abstract

The beta-chemokines RANTES (regulated on activation, normal T cell expressed and secreted), macrophage inflammatory protein-1alpha (MIP-1alpha), and MIP-1beta are the natural ligands of the HIV-1 coreceptor CCR5 and compete with the virus for receptor binding. We show that secretion of the beta-chemokines by activated lymphocytes starts before cellular DNA synthesis is detected and demonstrate that transient prolongation of the G(1) phase of the cell cycle by treatment with cytostatic drugs results in increased levels of the three chemokines in culture supernatants. Supernatants collected from peripheral blood mononuclear cells exposed to hydroxyurea, which arrests the cell cycle in late G(1), contained high levels of beta-chemokines. These supernatants were able to inhibit HIV-1 replication when added to cultures of infected lymphocytes. The observed antiviral effect likely was due to the increased levels of beta-chemokines RANTES, MIP-1alpha, and MIP-1beta because (i) supernatants greatly inhibited the replication of HIV-1 BaL, whereas they affected HIV-1 IIIb replication only slightly; (ii) neutralizing antibodies against the chemokines abrogated the antiviral effect of the supernatants; and (iii) the hydroxyurea concentrations shown to up-regulate chemokine levels were not sufficient to inhibit virus replication by depletion of intracellular nucleotide pools. Although antiviral properties have been reported previously for the cytostatic agents shown here to up-regulate beta-chemokine levels, our results provide an additional mechanism by which these drugs may exert antiviral activity. In summary, increased extracellular levels of anti-HIV-1 beta-chemokines resulting from transient prolongation of the G(1) phase of the lymphocyte cell cycle by treatment with cytostatic drugs may help to control the replication of CCR5-using strains of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644703      PMCID: PMC153068          DOI: 10.1073/pnas.0630584100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Increased beta-chemokine production in peripheral blood mononuclear cells derived from HIV-1-infected individuals by a cationic amphiphilic drug (AY 9944) in vitro.

Authors:  A Achour
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

2.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

3.  Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection.

Authors:  F Cocchi; A L DeVico; R Yarchoan; R Redfield; F Cleghorn; W A Blattner; A Garzino-Demo; S Colombini-Hatch; D Margolis; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle.

Authors:  N A Kootstra; B M Zwart; H Schuitemaker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.

Authors:  D Wang; C de la Fuente; L Deng; L Wang; I Zilberman; C Eadie; M Healey; D Stein; T Denny; L E Harrison; L Meijer; F Kashanchi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta in vitro is a correlate of reduced human immunodeficiency virus burden in vivo.

Authors:  J Ferbas; J V Giorgi; S Amini; K Grovit-Ferbas; D J Wiley; R Detels; S Plaeger
Journal:  J Infect Dis       Date:  2000-08-31       Impact factor: 5.226

7.  Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.

Authors:  Nicholas I Paton; Jamila Aboulhab; Fatimah Karim
Journal:  Lancet       Date:  2002-05-11       Impact factor: 79.321

8.  Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.

Authors:  Y D Korin; J A Zack
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Inhibition of sterol and DNA synthesis in peripheral blood lymphocytes by AY9944.

Authors:  G Kay; P A Wilce
Journal:  Biochem Biophys Res Commun       Date:  1983-01-14       Impact factor: 3.575

View more
  8 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

2.  Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.

Authors:  D De Forni; M R Stevens; F Lori
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.

Authors:  A Heredia; A Amoroso; C Davis; N Le; E Reardon; J K Dominique; E Klingebiel; R C Gallo; R R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-12       Impact factor: 11.205

Review 4.  HIV-1 viral protein R (Vpr) and its interactions with host cell.

Authors:  Ge Li; Michael Bukrinsky; Richard Y Zhao
Journal:  Curr HIV Res       Date:  2009-03       Impact factor: 1.581

5.  Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.

Authors:  Stephanie Oliere; Meztli Arguello; Thibault Mesplede; Vanessa Tumilasci; Peyman Nakhaei; David Stojdl; Nahum Sonenberg; John Bell; John Hiscott
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

Review 6.  Regulation of cell cycle proteins by chemokine receptors: A novel pathway in human immunodeficiency virus neuropathogenesis?

Authors:  Renato Brandimarti; Muhammad Zafrullah Khan; Alessandro Fatatis; Olimpia Meucci
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

7.  CDKN2A Deletion in Melanoma Excludes T Cell Infiltration by Repressing Chemokine Expression in a Cell Cycle-Dependent Manner.

Authors:  Zhen Zhu; Hao Song; Juan Xu
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

8.  VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

Authors:  Franco Lori; Davide De Forni; Elly Katabira; Denis Baev; Renato Maserati; Sandra A Calarota; Pedro Cahn; Marco Testori; Aza Rakhmanova; Michael R Stevens
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.